From Yahoo Finance: 2025-06-05 05:52:00

Summit Therapeutics Inc. (SMMT) saw a 5.14% drop in share prices to $19.56 on Wednesday, prompting investors to take profits after previous gains. Zacks Equity Research highlighted selling pressure, pushing the stock into oversold territory, but also suggested a potential turnaround.

Despite achieving its primary endpoint for progression-free survival with Ivonescimab and platinum-doublet chemotherapy, Summit Therapeutics Inc. (SMMT) faced investor disinterest, leading to a sell-off of shares. The stock currently holds a “buy” recommendation from Zacks, indicating a positive trend in earnings estimate revisions and EPS surprises.

Read more: Why Summit Therapeutics Inc. (SMMT) Crashed On Wednesday